Australia's most trusted
source of pharma news
Thursday, 03 April 2025
Posted 2 April 2025 AM
While the Albanese Government has been drip-feeding PBS listings as far out as May ahead of the Federal Election, there were still some surprise additions to the scheme this month.
Overall, there were nine additions to the scheme for April, including BeiGene’s Tevimbra for advanced or metastatic gastro-oesophageal cancer, which joins a growing list of PD-1 inhibitors on the PBS and marks the company’s second product subsided in Australia following Brukinsa.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.